

Revised: April 2024

Steven G. Wong, M.D.
Curriculum Vitae

PERSONAL HISTORY

Business Address

Cancer Center of Southern California/Sarcoma Oncology Research Center
2811 Wilshire Blvd., Suite 414
Santa Monica, CA 90403
310-552-9999
September 2017 to present

Medical Oncology and Hematology
William Isacoff, MD, Inc.
2811 Wilshire Blvd., Suite 420
Santa Monica, CA 90403
310-824-4133
sgwong@ucla.edu
February 2015-present

Uptimum Hematology/Oncology
2200 W. Manchester Blvd.
Inglewood, CA 90305
310-644-8400
December 2018 to present

Locum Tenens

Various practices throughout USA

CompHealth Locum Tenens

Inpatient Consultation, St Luke's Hospital Plaza, Kansas City, MO, June 2022 to August 2023

Inpatient Consultation, Kings Daughters Medical Center, Ashland KY, May 2021 to June 2021

Weatherby Locum Tenens

Inpatient Consultation, St Alphonsus Medical Center, Boise ID, August 2021

EDUCATION

Doctor of Medicine, MD
May 1993
UCLA School of Medicine
University of California, Los Angeles
August 1989 to May 1993

Revised: April 2024

Bachelor of Science, BS
Awarded June 1983
College of Letters and Science
University of California, Los Angeles
September 1978 to June 1983

Internship, Internal Medicine
July 1993- June 1994
Department of Medicine
UCLA School of Medicine
UCLA Medical Center

Residency, Internal Medicine
July 1994- June 1996
Department of Medicine
UCLA School of Medicine
UCLA Medical Center

Clinical Fellowship, Hematology and Medical Oncology
July 1996- June 1999
Division of Hematology/Oncology
Department of Medicine
UCLA School of Medicine
UCLA Medical Center

Postdoctoral Research Fellowship, Medical Oncology
July 1999- June 2002
Division of Hematology/Oncology
Department of Medicine
UCLA School of Medicine
UCLA Medical Center

LICENSURE

California

Issue Date: September 21, 1994
Expiration Date: May 31, 2026
Certificate G79910

Montana

Issue Date: September 11, 2014
Expiration Date: March 31, 2016
Certificate: MED-PHYS-LIC-34736

Revised: April 2024

Reissue Date: December 28, 2020
Expiration Date: March 31, 2024
Certificate: MED-PHYS-LIC-91663

Maine

Issue Date: February 2020
Expiration Date: February 19, 2023
Certificate: MD23655

Wyoming

Issue Date: April 9, 2015
Expiration Date: June 30, 2016
Certificate: 10105A

DEA California

Issue Date: 1994
Expiration Date: May 31, 2024
Certificate BW4290730

DEA Alaska

Issue Date: February 25, 2021
Expiration Date: May 31, 2027
Certificate: FW9108590

BOARD CERTIFICATION

Diplomate in Medical Oncology

American Board of Internal Medicine
Date Issued: 2000, Active through December 2024
Certificate #171275

Diplomate in Internal Medicine

American Board of Internal Medicine
Date Issued: 1997, Expired 2007.
Certificate #171275

PROFESSIONAL EXPERIENCE

Consultant Physician
William Isacoff, M.D., Inc.
Medical Oncology and Hematology
2811 Wilshire Blvd., Suite 414
Santa Monica, CA 90403
February 2015 to present

Consultant Physician
Sarcoma Oncology Center

Revised: April 2024

2811 Wilshire Blvd., Suite 414
Santa Monica, CA 90403
September 2017 to present

Consultant Physician
Uptimum Hematology/Oncology
2200 W. Manchester Blvd.
Inglewood, CA
December 2018 to present

Consultant Physician
Global Oncology, Inc
1411 S. Garfield Ave., Ste 306 & 308
Alhambra, CA 91801
November 2016 to April 2021

Consultant Physician (Locum Tenens)
Department of Medical Oncology
Billings Clinic Cancer Center
September 2014-January 2015

Associate Clinical Professor of Medicine and Urology
Institute of Urologic Oncology at UCLA
Division of Hematology/Oncology
Department of Medicine and Urology
David Geffen School of Medicine at UCLA
July 2012-August 2014

Assistant Clinical Professor of Medicine
Division of Hematology/Oncology
Department of Medicine and Urology
UCLA School of Medicine
July 2004-June 2012

Clinical Instructor of Medicine
Division of Hematology/Oncology
Department of Medicine
UCLA School of Medicine
July 2002-June 2004

STAR Research Postdoctoral Research Fellow
Specialty Training in Academic Research
Medical Oncology/Department of Biologic Chemistry

Revised: April 2024

UCLA Medical Center
July 1999- June 2002 (withdrew from Ph.D. Program)

Fellow, Hematology-Oncology
UCLA Medical Center
July 1996- June 1999

Resident, Internal Medicine
UCLA Medical Center
July 1994- June 1996

Intern, Internal Medicine
UCLA Medical Center
July 1993-June 1994

Staff Research Associate
Post-baccalaureate Research
Division of Hematology/Oncology
University of California, Los Angeles
August 1985- July 1989

Research Technician
Post-baccalaureate Research
INGENE, International Genetic Engineering, Inc.
August 1983- July 1985

PROFESSIONAL ACTIVITIES

Committee Service

Member, Medical Institutional Review Board at UCLA Medical Center
January 2006- August 2014

Member, Data, Safety and Monitoring Board at UCLA Medical Center
January 2007- August 2014

Professional Associations

American College of Physicians
January 1990-present

American Society of Clinical Oncologists
January 1996-present

American Association for Cancer Research
January 1996-present

Revised: April 2024

Scholarly Societies

Scientific Advisory Board, Emeritus Member
Bladder Cancer Advocacy Network (BCAN)
January 2008- December 2014

Bladder Cancer Think Tank
Bladder Cancer Advocacy Network (BCAN)
January 2009- December 2014

Committee Member
NCI Bladder Cancer Task Force
January 2010-December 2014

HONORS/AWARDS

Top 10% Medicine Faculty Teaching Annual Award
Internal Medicine Residency Program
University of Missouri, Kansas City
May 2023

Specialty Training in Academic Research Program
UCLA Department of Medicine
July 1997- June 2002

AMGEN Oncology Fellow
UCLA Division of Hematology/Oncology
UCLA School of Medicine
July 1997- June 1998

Dean's Scholar
Medical Student Thesis Project
UCLA Department of Medicine
June 1993

RESEARCH GRANTS AND FELLOWSHIPS

AMGEN Fellowship, Oncology Research, \$40,000
July 1997- June 1998

LECTURES AND PRESENTATIONS

Downstream Effects of HER-2/neu Amplification, Medical Student Thesis Project, UCLA School of Medicine, February 1993.

Revised: April 2024

Comprehensive Review of the Management of Back Pain, UCLA Department of Medicine Housestaff Noon Conference, November 1994.

Multiple Myeloma Review, UCLA Department of Medicine Housestaff Noon Lectures, October 1995.

Kaiser Permanente-Sunset, Department of Medicine Noon Conference, October 1996.

HER-2/neu in Breast Cancer, UCLA Division of Hematology-Oncology, Noon Conference, May 1998.

HER-2/neu in Breast Cancer, UCLA Division of Hematology-Oncology, Dinner Conference (Taninos), Los Angeles, May 2000.

Research at the UCLA Jonsson Comprehensive Cancer Center, UCLA/OrthoBiotech Summit, November 2000.

Angiogenesis Review, VEGF Family, Biological Chemistry Literature Seminars, Department of Biological Chemistry, UCLA School of Medicine, February 2001.

New Biological Therapies for Cancer, Wellness Community Conference, Westlake Village Wellness Community, Westlake Village, California, May 2005.

Supportive Care for Patients with Cancer, Wellness Community Conference, Westlake Village Wellness Community, Westlake Village, California, December 2005.

Testicular Cancer Review, Urology Grand Rounds, Department of Urology, Harbor-UCLA Medical Center, December 2006.

Management of Testicular Cancer, Hematology/Oncology Fellows Conference/Grand Rounds, UCLA Division of Hematology/Oncology, April 2007.

Breast Cancer: Review of Latest Treatment Advances, Wellness Community Conference, Westlake Village Wellness Community Center, Westlake Village, California, July 2007.

Clinical Management of Head and Neck Cancer, Prism Trial, Clinical Investigators Meeting, Amgen Sponsored, San Diego, August 2007.

Prostate Cancer, Now What? Clinical Review of Prostate Cancer Diagnosis and Multimodality Treatment, Insights into Cancer Lecture Series, Simms Mann Center for Integrative Oncology at UCLA, October 2007.

Head and Neck Cancer Review, Hematology/Oncology Fellows Conference/Grand Rounds, UCLA Division of Hematology/Oncology, January 2008.

Revised: April 2024

Livestrong Cancer Review for Patients with Cancer, Wellness Community Conference, Westlake Village Wellness Community, Westlake Village, California, February 2008.

Bladder Cancer Review, Hematology/Oncology Fellows Conference/Grand Rounds, UCLA Division of Hematology/Oncology, May 2009.

CA9 Gene Single Nucleotide Polymorphisms Predict Prognosis and Treatment Response of Metastatic Renal Cell Carcinoma, Presentation for Michela de Martino, Ph.D., Targeted Therapy in Metastatic Renal Cell Carcinoma: The Biology of Response, Resistance and Clinical Therapeutics, ASCO Annual Meeting, Orlando, Florida, June 2009.

Rare and Neglected Tumors: Bladder, Head and Neck and Adrenocortical Carcinomas, Hematology/Oncology Fellows Noon Research Conference/Grand Rounds, UCLA Division of Hematology/Oncology, October 2009.

Multimodality Management of Bladder Cancer, Hematology/Oncology Fellows Conference/Grand Rounds, UCLA Division of Hematology/Oncology, April 2010.

Breast Cancer Review, Patient Forum, Wellness Community Conference, Westlake Village Wellness Community, Westlake Village, California, January 2011.

Role of Chemotherapy in Urothelial/Bladder Cancer, Bladder Cancer Advocacy Network (BCAN) Patient Forum, Los Angeles, California, March 2011.

Translational Oncology Research at UCLA, the Discovery of HER-2 in Breast Cancer and Development of HER-2 Directed Therapy, Keynote Lecture, UCLA Dental School Annual Weintraub Retreat, Pasadena, California, March 2011.

Testicular and Germ Cell Neoplasms, A Model Disease for Multimodality Management, Hematology/Oncology Fellows Conference/Grand Rounds, UCLA Division of Hematology/Oncology, April 2011.

Bladder Cancer 2011, The Surgeon's and Medical Oncologist's Perspective, with Mark Litwin, M.D., Insights into Cancer Monthly Lecture Series, Simms Mann Integrative Oncology at UCLA, June 2011.

Adrenocortical Carcinoma, A Model Disease for Multidisciplinary Management, Endocrinology Grand Rounds, UCLA Division of Endocrinology, Department of Medicine, July 2011.

Head and Neck Cancer, Role of Systemic Therapy, Head and Neck Residents Conference, UCLA Department of Head and Neck Surgery, October 2011.

Revised: April 2024

Prostate Cancer, What Happens Next? 2011, Insights into Cancer Monthly Lecture Series, Simms Mann Integrative Oncology at UCLA, December 2011.

Management of Adrenocortical Carcinoma, Role of Systemic Therapy, 2012, Annual Scientific Meeting of the Southern California Chapter of the American College of Surgeons, Santa Barbara, California, February 2012.

Bladder Cancer, Review of Clinical Management, Hematology/Oncology Fellow Noon Conference, Grand Rounds, UCLA Division of Hematology/Oncology, April 2012.

Testicular and Germ Cell Neoplasms, Fellows Noon Conference, UCLA Division of Hematology, Institute of Urologic Oncology at UCLA, February 2013.

Translational Oncology Research, Lessons from the HER-2 Studies at UCLA, American Urologic Association/European Association of Urology Exchange Scholars Program, UCLA Department of Urology and Division of Hematology/Oncology, Institute of Urologic Oncology at UCLA, April 2013.

An Overview of Bladder Cancer with Focus on the Role of Chemotherapy, UCLA Jonsson Comprehensive Cancer Center Clinical Research Unit Brown Bag Symposium State of the Disease Lecture Series, August 2013.

Bladder and Urinary Tract Cancers, Review of Signs, Symptoms, and Treatments, Community Health Programs, Cancer Support Community, West Los Angeles, October 2013.

Prostate Cancer, Case Series and Clinical Review, Medical Residents Noon Conference Series, Billings Clinic Cancer Center, October 2014.

BIBLIOGRAPHY

Peer Reviewed Journals

1. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W., Ullrich, A., McGuire, W.L.: "Human Breast Cancer: Correlation of Relapse and Survival with Amplifications of the HER-2/neu Proto-oncogene." *Science*, Vol. 235, pp. 177–182. (1987).
2. Slamon, D.J., Godolphin, W., Jones, L., Holt, J., Wong, S.G., Keith, D., Levin, W., Stuart, S., Udove, J., Ullrich, A., Press, M.: "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer." *Science*, Vol. 244, pp. 707–712. (1989).
3. Ronco, L.V., Silverman, S.L., Wong, S.G., Slamon, D.J., Park, L., Gasson, J.C.: "Identification of Conserved Amino Acids in the Human Granulocyte-Macrophage Colony-stimulating Factor Receptor Alpha Subunit Critical for Function." *The Journal of Biological Chemistry*, Vol. 269, No. 1, pp. 277–283, January 7. (1994).

Revised: April 2024

4. Yates, K.E., Lynch, M.R., Wong, S.G., Slamon, D.J., and Gasson, J.C.: "Human c-Fes Is a Nuclear Tyrosine Kinase Involved in Erythropoietin and IL-3 Signaling." *Oncogene*, Vol. 10, pp. 1239–1242. (1995).
5. Oh, J.O., Grosshans, D.R., Wong, S.G., and Slamon, D. J.: "Identification of Differentially Expressed Genes Associated with HER-2/neu Overexpression in Human Breast Cancer Cells." *Nucleic Acid Research*, Vol. 27, No. 20, pp. 4008–4017, October 15. (1999).
6. Ilagan, R., Potratz, J., Le, K., Zhang, L., Wong, S.G., Ayala, R., Iyer, M., Wu, L., Gambhir, S.S., and Carey, M.: "Imaging Mitogen-Activated Protein Kinase Function in Xenograft Models of Prostate Cancer." *Cancer Research*, Vol. 66, pp. 10778–10785, November 15. (2006).
7. Sadeghi, S., and Wong, S.G.: "Accurate Testing for HER2/neu Oncogene Overexpression." *Proceedings of the UCLA Healthcare Journal*, Vol. 12. (2008).
8. Wong, S.G., Damiani, T., and Sadeghi, S., "Adrenocortical Carcinoma: A Rare Endocrine Malignancy with Variable Clinical Behavior, Review of a Case Series." *Proceedings of UCLA Healthcare Journal*, Vol. 13. (2009).
9. Soon, P.S., Tacon, L.J., Sywak, M.S., Campbell, P., Yeh, M.W., Wong, S.G., Clifton-Bligh, R., Robinson, B.R., and Sidhu, S.B., "QS130. MicroRNA Microarray Analysis of Human Adrenocortical Tumors", *Journal of Surgical Research* 151(2):288-288 · January (2009)
10. Britten, C.D., Finn, R.S., Bosserman, L.D., Wong, S.G., Press, M.F., Malik, M., Lum, B.L., and Slamon, D.J., "A Phase I/II Trial of Trastuzumab Plus Erlotinib in Metastatic HER2-Positive Breast Cancer: A Dual ErbB Targeted Approach." *Clinical Breast Cancer*, Vol. 9, No. 1, pp. 16-22, February. (2009).
11. Klatte, T., Seligson, D.B., Rao, J.Y., Yu, H., de Martino, M., Kawaoka, K., Wong, S.G., Beldegrun, A.S., and Pantuck, A.J., "Carbonic Anhydrase IX in Bladder Cancer: A Diagnostic, Prognostic, and Therapeutic Molecular Marker." *Cancer*, Vol. 115, No. 7, pp. 1448-1458, April 1. (2009).
12. Soon, P.S., Tacon, L.J., Gill, A.J., Bambach, C.P., Sywak, M.S., Campbell, P.R., Yeh, M.W., Wong, S.G., Clifton-Bligh, R.J., Robinson, B.G., and Sidhu, S.B., "miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer." *Clinical Cancer Research*, Vol. 15, No. 24, pp. 7684-7692, December 15. (2009).
13. Klatte, T., Seligson, D.B., Rao, J.Y., Yu, H., de Martino, M., Garraway, I., Wong, S.G., Beldegrun, A.S., and Pantuck, A.J., "Absent CD44v6 Expression Is an Independent Predictor of Poor Urothelial Bladder Cancer Outcome." *Journal of Urology*, Vol. 183, pp. 2403-2408, June. (2010).
14. Janne, P.A., Boss, D., Camidge, D.R., Britten, C.D., Engleman, J.A., Garon, E.B., Guo, F., Wong, S., Liang, J., Letrent, S., Millham, R., Taylor, I., Eckhardt, S.G., and Schellens, J.H., "Phase I Dose Escalation Study of the Pan-HER Inhibitor,

- PF00299804, in Patients with Advanced Malignant Solid Tumors.” *Clinical Cancer Research*, Vol., 17, pp. 1131-1139, March. (2011).
15. Sadeghi, S., and Wong, S.G., “Review of Angiogenesis in Ovarian Cancer.” *Proceedings of the UCLA Healthcare Journal*, October. (2011).
16. Ather, F., Hamidi, H., Fejzo, M.S., Letrent, S., Finn, R.S., Kabbinavar, F., Head, C., Wong, S.G., “Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab.” *PLoS One*, Vol. 8, No. 2, p. e56112, February. (2013).
17. Grivas, P.D., Daignault, S., Tagawa, S.T., Nanus, D.M., Stadler, W.M., Dreicer, R., Kohli, M., Petrylak, D.P., Vaughn, D.J., Bylow, K.A., Wong, S.G., Sottnik, J.L., Keller, E.T., Al-Hawary, M., Smith, D.C., Hussain, M., “Double-Blind, Randomized, Phase 2 Trial of Maintenance Sunitinib Versus Placebo After Response to Chemotherapy in Patients with Advanced Urothelial Carcinoma.” *Cancer*, March. (2014).
18. Olevsky, O., and Wong, S.G., Diagnosis and Management of Von Willebrand Disease, *Proceedings of the UCLA Healthcare*, Volume 18, (2014).
19. Wong, S.G., Gayed, M., Olevsky, O., Sadeghi, S., and Drakaki, A.: “Case Vignette: Mistaken Identity. Penile Cancer in the Setting of Bladder Carcinoma, Potential Confusing Histopathologic Diagnoses.” *Proceedings of the UCLA Healthcare Journal*. (2014).
20. Shin, D.S., Sherry, T., Kallen, M.E., Wong, S.G., Drakaki, A., “Human Epidermal Growth Factor 2 (Her2/neu) Directed Therapy for Rare Epithelial Tumors with Her2 Amplification.” *Case Reports in Oncology*, Vol. 9, No. 2, pp 298-304, June (2016).
21. Wong, S.G., Wong, M.J., and Sadeghi, S. “How to Make a Scary Situation Less Scary... Prostate Cancer Gone Awry, a Remarkable Case Report, Clinical Vignette, *Proceedings of the UCLA Healthcare Journal*, Vol. 20, (2018).
22. Chawla, S.P., Wong, S.G., Quon, D., Moradkhani, A., Chua, V.S., Brigham, D.A., Reed, R.A., Swaney, W., Hall, F.L., Gordon, E.M.; “Three Year Results of Blessed: Expanded Access for. DeltaRex-G for an Intermediate Size Population with Advanced Pancreatic Cancer and Sarcoma (NCT04091295) and Individual Patient Use of DeltaRex-G for solid malignancies (IND#19130).” *Frontiers in Molecular Medicine*, Vol. 2 (2022).
23. Gordon, E.M., Chawla, S.P., Tellez, W.A., Younesi, E., Thomas, S., Chua-Alcala, V., Chomoyan, H., Valencia, C., Brigham, D.A., Moradkhani, A., Quon, D., Srikureja, A., Wong, S.G., Tseng, W., Federman, N.; SAINT: A Phase 1/Expanded Phase 2 Study Using Safe Amounts of Ipilimumab, Nivolumab, and Trabectedin as First-Line Treatment Advanced Soft Tissue Sarcoma, *Cancers*, Vol. 15, p. 906 (2023).
24. Gordon, E.M., Angel, N.L., Omelchenko, N., Chua-Alcala, V.S., Moradkhani, A., Quon, D., and Wong, S.G. *A Phase I/II Investigation of Safety and Efficacy of Nivolumab and nab-Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway*, *Anticancer Research* 43: 1993-2002 (2023)

Promotional Speaker Bureau Lectures

1. Xtandi (enzalutamide) capsules: Inhibiting the Androgen Receptor Signaling Pathway at Multiple Steps, Multiple locations (Dinner and Lunch seminars), Supported by Astellas-Medivation. 2014-2015.
2. Lazanda (fentanyl) nasal spray: Route to Confident Control, Multiple sites (Breakfast, Lunch and Dinner seminars), Supported by Depomed, January 2015 to 2017. Supported by West Therapeutics Development, November 2018 to June 2019.
3. Tecentriq (atezolizumab) injectable: Tecentriq (atezolizumab) Injection, for Intravenous Use, in Previously Treated Locally Advanced or Metastatic Urothelial Cancer, Supported by Genentech, April 2016-April 2018.
4. Subsys (fentanyl) oral spray: Breakthrough Cancer Pain and Its Treatment, Supported by Insys, January 2017-December 2019.
5. Imfinzi (durvalumab) injectable: Immuno-Oncology Therapy for Patients with Advanced Urothelial Carcinoma Previously Treated with Chemotherapy, Supported by Astra Zeneca. February 2018-December 2019.
6. Syndros (dronabinol) oral solution: The Only FDA Approved Liquid Dronabinol Targeting the Canniboid Receptor, Supported by Insys, December 2017-June 2019.
7. Copiktra (duvelisib) tablets: Copiktra (duvelisib), Clinical Overview. Multiple Locations, Supported by Verastem, February 2019-2020.
8. Tavalisse (fostamatinib) tablets: First and Only Syk Inhibitor for Immune Thrombocytopenia (ITP). Multiple Locations. Supported by Rigel, March 2019-2020.

Manuscripts Submitted for Publication

Abstracts

1. Yates, K.E., Lynch, M.R., Wong, S.G., Slamon, D.J., and Gasson, J.C.: *The Fes Nuclear Tyrosine Kinase Functions in IL-3 and EPO Signaling*. American Society of Hematology, 36th Annual Meeting. 1994.
2. Peng, H.J., Einhorn, P.A., Wong, S.G., Arboleda, J., Ramos, B.L., Reynolds, C.P., Slamon, D.J.: *N-myc Transduction into Human Neuroblastoma Cells Enhances Aggressive Behavior*. American Association for Cancer Research, Annual Meeting. 1995.
3. Reissmann, P.T., Wong, S.G., Jourdan, L.J., Gao, C., Pruitt, S., Chazin, V.R., Slamon, D.J.: *Increased Expression of MyD116/GADD34 Induced by HER2/neu Overexpression*. American Association for Cancer Research, 89th Annual Meeting. 1998.

4. Reissmann, P.T, Wong, S.G., Jourdan, L.J., Gao, C., and Slamon, D.J.: *MyD116/GADD34 Is Upregulated by HER-2/neu Overexpression, and Enhances Proliferation and Tumorigenicity of MCF-7 Cells*. American Association for Cancer Research, 90th Annual Meeting. 1999.
5. Wong, S.G., Glaspy, K., Jones, K., Slamon, D.J.: *Prostate Cancer and Immortalized Cell Lines Exhibit Enhanced Growth Inhibition with Combined Epidermal Growth Factor Inhibition and Androgen Receptor Blockade*. American Association for Cancer Research/ National Cancer Institute of Health/European Organization for Research and Treatment of Cancer, International Conference of Molecular Targets and Cancer Therapeutics. 2003.
6. Ilagan, R.S., Pottratz, J.K., Le, K.H., Wong, S.G., Ayala, R., Slamon, D.J., Carey, M.F.: *Bioluminescence Imaging of AR and MAPK Activity in Androgen Independent Prostate Cancer Xenografts*. American Association for Cancer Research, 96th Annual Meeting. 2005.
7. Paiva, M.B., Bublik, M., Wong, S., Blackwell, K.B., Sercarz, J.: “Minimally Invasive Laser-induced Thermal Therapy (LITT) for Head and Neck Cancer: A Comprehensive Review.” *Journal of Clinical Oncology*, ASCO Annual Meeting Proceedings Part I, Vol. 24, No. 18S (June 20 Supplement), Abstract #5572. 2006.
8. Wong, S.G., Springer, J., Fox, D., Venkatesan, N., and Head, C.: *Head and Neck Squamous Carcinoma Cell Lines Exhibit an Intact EGFR Signaling Pathway and Variable Response to EGFR Agonist and Antagonist*. 18th European Organization for Research and Treatment of Cancer/National Cancer Institute/American Association for Cancer Research, Annual Meeting, Prague. 2006.
9. Schellens, J.H., Britten, C.D., Camidge, D.R., Boss, D., Wong, S.G., Diab, S., Guo, F., Maguire, R.P., Letrent, S.P., and Eckhardt, S.G.: “First-in-human Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of PF-00299804, a Small Molecule Irreversible PanHER Inhibitor in Patients with Advanced Cancer.” *Journal of Clinical Oncology*, ASCO Annual Meeting Proceedings Part I, Vol. 25, No. 18S (June 20 Supplement), Abs. 3599, 2007.
10. Camidge, D., Britten, C., Schellens, J., Guo, F., Millham, R., Eckhardt, S., Wong, S.G., Boss, D., Lucca, J., Janne, P.: *First-in-human Study of PF-00299804, a Small Molecule Irreversible PanHER Inhibitor in Patients with Advanced Cancer: Update on Safety and Pharmacokinetics And Initial Report on Pharmacodynamics Responses and Clinical Benefit*. American Association for Cancer Research Annual Meeting Abstracts, B229, October. 2007.
11. Janne, P.A., Schellens, J.H., Engelman, J.A., Eckhardt, S.G., Millham, R., Denis, L.J., Britten, C.D., Wong, S.G., Boss, D.S., Camidge, D.R.: “Preliminary Activity and Safety Results from a Phase I Clinical Trial of PF-00299804, an Irreversible PanHER Inhibitor, in Patients with NSCLC.” *Journal of Clinical Oncology*, ASCO Annual Proceeding Part I, Vol. 26, No. 15S, Abs. 8027, May 20. 2008.
12. Klatte, T., Seligson, D.B., Rao, J.Y., Yu, H., de Martino, M., Kawaoka, K., Garraway, I., Wong, S.G., Belldegrun, A., and Pantuck, A.J.: *Absence of CD44 Expression Is an*

- Independent Predictor of Poor Outcome for Patients with Urothelial Bladder Cancer.* AUA Annual Meeting, May-June. 2008.
13. Wong, S.G., Ather, F., Head, C.: *Study of Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines Demonstrates Variable Response to HER/EGFR Directed Therapy.* Annual UCLA Department of Medicine Research Day, October. 2008.
 14. Schellens, J.H., Guo, F., Janne, P.A., Eckhardt, S.G., Camidge, D.R., Taylor, I., Lucca, J., Boss, D., Wong, S.G., and Britten, C.D.: *First-in-human Study of PF-00299804 in Advanced Cancer Patients: Correlation Between Pharmacokinetics and Pharmacodynamics.* Annual Meeting, Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, AACR-NCI-EORTC 2008, Geneva, October. 2008.
 15. Ather, F., Venkatesan, N., Wong, S.G.: *Investigations of Signaling Pathways and Molecular Characteristics of Head and Neck Squamous Cell Carcinoma Cell Lines Demonstrates Response to HER/EGFR Directed Therapy Acts Primarily Through the MAPK Pathway and G0/G1 Cell Cycle Arrest.* Annual UCLA Department of Medicine Research Day, October. 2009.
 16. Pastor, M., Frew, T., Wong, S.G.: *Study of HER Directed Modulation in Human Bladder Cancer Cell Lines.* Annual UCLA Department of Medicine Research Day, October 2009.
 17. Frew, T., Wong, S.G.: *Adrenocortical Carcinoma: A Study of Expression Profiles and Clinical Demographics.* Annual UCLA Department of Medicine Research Day, October. 2009.
 18. Pastor, M., Wong, S.G.: *Phosphatidylinositol-3-kinase Inhibition in a Panel of Human Urothelial Bladder Carcinoma Cell Lines.* Annual UCLA Department of Medicine Research Day, October. 2010.
 19. Ather, F., Wong, S.G.: *Investigation of Four PI3K/AKT/mTOR Small Molecule Inhibitors Demonstrates Heterogeneous Response in a Panel of 30 Head and Neck Squamous Cell Carcinoma Cell Lines.* Annual UCLA Department of Medicine Research Day, October. 2010.
 20. Pastor, M., Frew, T., Yeh, M., Wong, S.G.: *Molecular Analysis of Adrenocortical Carcinoma (ACC) Tumors,* 2011 ASCO Annual Meeting, Chicago, IL, June. 2011.
 21. Pastor, M., Hamidi, H., Finn, R., Slamon, D., Wong, S.: *HSP90 Inhibitor Small Molecule Inhibitor (AUY922) Growth Inhibitor in Bladder Cancer Is Significant and Subtype Specific.* Annual UCLA Department of Medicine Research Day, October. 2011.
 22. Wong, S.G., Hamidi, H., Ather, F., Letrent, S., Venkatesan, N., Finn, R., Head, C.: *Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models that Exhibit Low Response to Cetuximab.* Multidisciplinary Head and Neck Cancer Meeting, ASTRO Annual Special Meeting February. 2012.
 23. Felo, N., Hamidi, H., Finn, R., Slamon, D., Wong, S.G., *FGFR Inhibitor (Brivanib) Growth Inhibition in Bladder Cancer.* Annual UCLA Department of Medicine Research Day, October. 2013.

24. Kabbinavar, F.F., Zomorodian, N., Belldegrun, A.S., Wong, S.G., Bot, A., Chodon, T., Comin-Anduix, B., Nguyen, P., Khan, F., Rettig, M., Pantuck, A., *A Phase I, Open Label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells (DC) Transduced with AdGMCA9 (DC-AdGMCAIX) in patients with mRCC*. ASCO Genitourinary Cancers Symposium, San Francisco, February 2014.
25. Sequist, L.V., Cassier, P., Varga, A., Tabernero, J., Schellens, J.H.M., Delord, J.P., LoRusso, P., Camidge, D.R., Medina, M.H., Schuler, M., Campone, M., Tian, G.G., Wong, S.G., Corral, J., Isaacs, R., Sen, S.K., Porta, D.G., Kulkarni, S.G., Lefebvre, C., Wolf, J., *Phase I Study of BGJ398, a Selective Pan-EGFR Inhibitor in Genetically Preselected Advanced Solid Tumors*, AACR Annual Meeting, San Diego, April 2014.
26. Felo, N., Nguyen, P., Wong, M., Wong, S.G., and Drakaki, A., *Treatment of metastatic urothelial carcinoma in a randomized double blinded clinical study test a novel HSP27 antisense mRNA inhibitor, OGX427*, UCLA Department of Medicine Annual Research Day, Los Angeles, October 2014.
27. Sherry, T., Shin, D., Drakaki, A., and Wong, S.G., *Molecular Oncology: HER2 Amplification found in uncommon disease states; Molecular Analysis of Tumors*, UCLA Department of Medicine Annual Research Day, Los Angeles, (Abstract only) October 2014; also presented UCLA DOMRD (Abstract and Poster) October 2015 and Drexel University, Discovery Day (Abstract and Poster), October 2015.
28. Gordon, E.M., Chua-Alcala, V.S., Kim, K., Quon, D.V., Wong, S.G., Chawla, S.P.; Sarcoma Oncology Research Center, Santa Monica, CA; Sarcoma Oncology Center, Santa Monica, CA; Los Angeles, CA; UCLA, Los Angeles, CA, *A phase 1b investigation of safety/efficacy of nivolumab and ABI-009 (nab-rapamycin) in advanced undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), chondrosarcoma (CS), osteosarcoma (OS) and Ewing sarcoma*. Abstract 230055, ASCO Annual Meeting, Chicago June 2018
29. Gordon, E.M., Chua-Alcala, V.S., Kim, K., Baby, R., Angel, N., Quon, D., Wong, S.G., Chawla, S.P.; Sarcoma Oncology Research Center, Santa Monica, CA; Sarcoma Oncology Center, Santa Monica, CA; Los Angeles, CA; UCLA, Los Angeles, CA, *A phase 1b investigation of nivolumab and ABI-009 (nab-rapamycin) in advanced undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), chondrosarcoma (CS), osteosarcoma (OS) and Ewing sarcoma, Preliminary Efficacy and Safety Results.* Abstract 11057, ASCO Annual Meeting, Chicago June 2019.
30. Gordon, E.M., Chua-Alcala, V.S., Kim, K., Stendahl Dy, P., Paz, M.K., Angel, N., Moradkhani, A., Quon, D., Wong, S., Jafari, O., Chawla, S.P.; *SAINT: Results of an expanded phase II study using safe amounts of ipilimumab (I), nivolumab (N), and trabectedin (T) as first-line treatment of advanced soft tissue sarcoma* [NCT03138161] Abstract 11520, ASCO Annual Meeting, Scientific Program, ASCO Annual Meeting, Scientific Program, Chicago, June 2020.
31. Chawla, S.P., Chua-Alcala, V.S., Kim, K., Stendahl Dy, P., Paz, M.K., Angel, N., Wang, K., Moradkhani, A., Quon, D., Wong, S.G., Jafari, O., Gordon, E.M.; *The TNT protocol: A phase II study using talimogene laherparepvec (TVEC), nivolumab (N) and trabectedin (T) as first, second/third line therapy for advanced sarcoma, including*

Revised: April 2024

desmoid tumor and chordoma. Abstract #: [TPS11572](#) ASCO Annual Meeting, Scientific Program, Chicago, June 2020.

32. Gordon, E.M., Chawla, S.P., Tellez, W.A., Younesi, E., Thomas, S., Valencia, C., Ahari, A., Chua, V., Chomoyan, H., Brigham, D.A., Moradkhani, A., Quon, D., Srikureja, A., Wong, S.G., Tseng, W., Federman, N.; *SAINTE: Five Year Results of a Phase 2 Trial Using Ipilimumab, Nivolumab, and Trabectedin for Previously Untreated Advanced Soft Tissue Sarcoma*. Abstract: 2206754 CTOS Annual Meeting, Vancouver, BC, November 2022.

33. Orosco, L., Omelchenko, N., Makrievski, S., Leão De Melo, G., Chawla, N.S., Brigham, D., Ahari, A., Chua, V., Quon, D., Moradkhani, A., Wong, S.G., Chawla, S.P., MD, and Gordon, E.M. *Update on GALLANT Phase 2 Study: A Metronomic Regimen Using Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Leiomyosarcoma*, Abstract ID: 1569806 CTOS Annual Meeting Dublin Ireland, November 2023.

34. Gordon, E., Chawla, S., Omelchenko, N., Jeffrey, S., Agarwal, A.D., Chawla, N., Chua Alcala, V., Quon, D., Wong, S. *Linnovate: A Phase 1-2 Study of Safety/Efficacy using Lurbinectedin Combined with Ipilimumab and Nivolumab for Advanced Soft Tissue Sarcoma: Interim Analysis of Phase 1 Part..* September 2024.